Fermenta Biotech Ltd.
Snapshot View

313.85 +0.50 ▲0.2%

02 August 2021, 04:00:00 P.M.
Volume: 30,711

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.fermentabiotech.com
Financial Indicators
Market Cap 922.22 Cr.
Earnings per share (EPS) 15.46 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 20.27 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 122.62 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.56 Calculated using Price: 313.35
Dividend Yield 1.60 Period Ending 2020-03
No. of Shares Subscribed 2.94 Cr. 29,430,987 Shares
FaceValue 5
Company Profile

DIL Ltd. formerly Duphar-Interfran Limited is an Indian public listed company located at Thane, India. Founded in 1951 by Late Dr. D V K Raju in the name of International Franchises Private Limited. DIL has built successful partnerships with leading multinational companies for over 53 years. The name of the company was then changed to ‘Crookes Interfran Limited’ and then in 1971 the name was changed to ‘Duphar Interfran Ltd.’. In the year 1976, the company’s equity shares were listed on the Stock Exchange of Bombay (BSE). In 2000, the company demerged its pharmaceutical business into a new company called Duphar Pharma India Ltd. (currently known as Solvay Pharma India Ltd.) which issued to the shareholders of Duphar Interfran Ltd., 2 equity shares of Duphar Pharma India Ltd. for every 1 share held in Duphar Interfran Ltd. by the shareholders at that time, while retaining their original share in Duphar Interfran Ltd. The name of the company was then changed to DIL Limited.

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

With the growing global need for newer drugs and for research, DIL, with its capabilities, becomes a preferred partner for undertaking contract research and custom synthesis.

Specializing in synthesis of fine organic compounds, chiral building blocks and Intermediates, their expertise include developing small size, aromatic & non-aromatic, functionalized heterocycles, enzyme mediated asymmetric synthesis of hydroxyesters, protection of amino acids at amino and carboxyl functionalities and synthesis of compounds having peptide linkage.

From its fully-equipped and modern facilities, the multi-cultural team at DIL strives to offer the best services in organic synthesis and industrial biotechnology.  Qualified synthetic chemists develop and produce tailor-made compounds (Gms to multi-kegs) for the pharmaceutical and biotechnology industries. Their services cover both individual projects, as well as working exclusively as permanent team members for clients.

Offering expertise on both short and long-term projects, DIL seamlessly blends in as an extension of the client company, offering flexible and integrated services, made to measure solutions, cost-effective and on-time service accelerating drug discovery and development – backed by the assurance of confidentiality.

With all this, DIL enhances and adds value to the client’s research program. DIL is a public listed company delivering reliable services to the pharmaceutical and biotechnology industries. Tucked away in a quiet and verdant niche in Thane, (32 km. away from Mumbai), and spread over 28,000 sq mts of land, is where it all happens.

Business area of the company:

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

Milestones:

  • 1951 – 1963: Toll manufacturing for the pharmaceutical and cosmetics industries.
  • 1963: The company established a JV with Philips Duphar for the manufacture and marketing of pharmaceutical products in India.
  • 1976: DIL was listed on the Bombay Stock Exchange.
  • 1980: Philips Duphar was taken over by Solvay Pharmaceuticals.
  • 1986: Fermenta Biotech Ltd. was founded as a subsidiary company to complement and segregate DIL’s capabilities in biotechnology.
  • 1987: Fundamental research was initiated as part of Solvay’s research efforts. A full-fledged laboratory was set up as per GLP requirements and accredited by the Department of Scientific & Industrial Research.
  • 1995: ‘Crocin’, which went on to become the most popular brand of paracetamol in India, was divested to SmithKline Beecham.
  • 2000: The company realigned its business to focus sharply and exclusively on custom synthesis and process R&D by de-merging its pharmaceutical formulation business in favour of Solvay.

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.16%
1 Week
-1.63%
1 Month
-2.29%
3 Month
-0.54%
6 Month
+4.18%
1 Year
+6.03%
2 Year
+35.97%
5 Year
+442.06%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 22.02 5.01 8.47 0.72 2.08 -6.00 40.79 64.77 21.92
Return on Capital Employed (%) 24.01 8.72 10.54 3.68 6.18 1.96 33.86 40.16 12.98
Return on Assets (%) 13.91 2.91 4.55 0.37 0.99 -2.76 15.85 25.73 10.75

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 129 127 133 132 130 144 124 251 309
Non Curr. Liab. 22 20 33 14 24 48 146 125 72
Curr. Liab. 45 58 71 94 108 86 104 156 195
Minority Int. 20 20 22 22 26 28 11 0 0
Equity & Liab. 216 226 259 262 288 307 385 532 576
Non Curr. Assets 101 129 145 171 195 203 202 226 292
Curr. Assets 116 97 114 91 93 104 182 296 284
Misc. Exp. not W/O 10
Total Assets 216 226 259 262 288 307 385 532 576

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 130 117 139 142 155 164 303 405 293
Other Income 4 2 3 0 1 3 11 27 14
Total Income 133 118 142 142 156 167 314 431 307
Total Expenditure -88 -94 -113 -126 -135 -152 -212 -269 -229
PBIDT 45 25 30 16 21 15 102 162 79
Interest -4 -5 -5 -5 -6 -10 -14 -21 -20
Depreciation -8 -9 -10 -9 -8 -10 -12 -12 -15
Taxation -6 -4 -3 -2 -4 -3 -21 -11 16
Exceptional Items
PAT 27 6 11 1 3 -8 55 118 60

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 39 23 14 15 4 2 59 90 34
Cash Fr. Inv. -50 -20 -25 -18 -13 7 -101 -97 -44
Cash Fr. Finan. 7 -8 13 1 10 -12 89 12 -47
Net Change -4 -4 2 -2 1 -4 47 6 -57
Cash & Cash Eqvt 8 4 6 3 5 -15 32 38 -18

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 62.59 63.15 59.44 59.44 59.44 59.44 59.44 59.44 59.44
Public 37.41 36.85 40.56 40.56 40.55 40.55 40.55 40.55 40.55
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 27 Jul 2021
Related Party Transactions Under Regulation 23 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ('Listing Regulations')
In connection with our earlier intimation dated June 29 2021 regarding the Outcome of the Board Meeting for approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31 2021 and in accordance with Regulation 23 of Listing Regulations we are enclosing herewith the disclosure of Related Party Transactions on a consolidated basis for the half year ended March 31 2021.

This information will also be made available at https://www.fermentabiotech.com/investor_relations.php
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Fermenta Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 19 Jul 2021
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayFermenta Biotech Ltd
2CINL99999MH1951PLC008485
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 134.28
4Highest Credit Rating during the previous FY A-
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Srikant Sharma
Designation: Company Secretary & Vice President (Legal)
EmailId: srikant.sharma@fermentabiotech.com
Name of the Chief Financial Officer: Sumesh Gandhi
Designation: Chief Financial Officer
EmailId: sumesh.gandhi@fermentabiotech.com

Date: 19/07/2021

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Technical Scans View Details

Fri, 30 Jul 2021
Opening at High Opening at High
ROC Trending Down ROC Trending Down
Thu, 29 Jul 2021
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.45 +0.1%
Divi's Laboratories Ltd. 129,702.64 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,701.80 -0.2%
Cipla Ltd. 74,235.31 921.80 +0.2%
Cadila Healthcare Ltd. 59,986.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,049.00 +0.4%
Aurobindo Pharma Ltd. 53,701.27 918.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.87 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 918.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.05 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 918.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 918.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 918.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 918.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 918.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 918.00 +0.1%